Biotech Startups

OncoInsight develops off-the-shelf natural killer (NK) cell therapy product candidates aimed at treating cancer patients. The company operates in the biotech and cell therapy space.

1 investor

Oncoliq develops early cancer detection technology that combines molecular biology and machine learning to offer a non-toxic, non-invasive, and low-cost diagnostic approach. The company operates in the cancer diagnostics field.

1 investor

A clinical research organization that conducts clinical trials to provide innovative therapies to patients in specific medical conditions at no additional cost.

1 investor

OncoLux develops an optical theranostic system that gives surgeons intraoperative enhanced visualization of residual cancer and combines it with optical photodynamic therapy to treat remaining tumor tissue during surgery. The technology targets cancer surgery patients and clinicians in the medical device field.

1 investor

OncoNano Medicine develops a proprietary nanotechnology platform for cancer therapeutics that targets the acidic tumor microenvironment to improve drug delivery to tumors. The company serves oncology patients and builds a pipeline of therapies designed for more precise cancer treatment.

1 investor

OncoRevive develops a multiomics blood test combining nanotechnology, cancer biology, and AI to detect and monitor cancer in less than 2 hours at a fraction of current costs. The test is designed for healthcare providers, hospitals, and pathology labs seeking rapid, comprehensive same-day cancer diagnostics.

1 investor

OncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.

1 investor

Oncostellae is a biotech company developing novel JAK inhibitors for the treatment of inflammatory bowel disease and cancer, with a focus on local, gut-restricted therapies that minimize systemic toxicity.

1 investor

OncoSwab develops a nasal swab-based sampling platform that captures airway-derived genetic material to detect ctDNA and cancer-associated biomarkers at the origin of lung cancer, complementing blood-based liquid biopsy. It is offered as a Research Use Only tool for researchers running lung cancer biomarker, longitudinal, and multi-site studies while clinical validation is underway.

1 investor

Oncosyne develops functional biology tools and preclinical models for cancer drug development and patient stratification, serving oncology drug developers and precision medicine researchers.

1 investor

OncoSynergy is a clinical-stage immuno-oncology company developing monoclonal antibody therapeutics, including a pan-CD29 antibody and a PD1-targeting antibody. It operates in the biotech and cancer drug development space.

1 investor

Oncotarget is a peer-reviewed academic journal publishing oncology and cancer research papers, indexed in databases such as PubMed, MEDLINE, and Scopus. It is operated by Rapamycin Press LLC (dba Impact Journals) and serves researchers and investigators in cancer research and medicine.

1 investor

1 investor

Oncoxome develops an oral delivery platform for cancer therapies that targets tumor cells directly with minimal off-target toxicity. The platform enables delivery of various therapeutic modalities including CRISPR, siRNA, mRNA, and proteins to cancer patients.

1 investor

Clinical-stage oncology company developing cancer treatments

1 investor

1 investor

1 investor

A biotechnology company focused on developing therapeutics related to genetic regulation of longevity and aging processes, with expertise in drug development and clinical trials.

1 investor

OneChain Immunotherapeutics is a clinical-stage biotech developing CAR-T cell therapy candidates as treatments for oncological diseases. It is a spin-off from the Josep Carreras Leukemia Research Institute and ICREA, based on research led by Dr. Pablo Menéndez's team.

1 investor

OneKind develops AI-driven computer vision software that converts behavioral video data into validated clinical endpoints for animal health studies, beginning with pruritus detection in canine and feline dermatology trials. The platform replaces subjective manual observation with automated, frame-level behavioral measurement to improve statistical rigor and reduce measurement variability in veterinary clinical research.

1 investor

Onego Bio produces Bioalbumen®, a fermentation-derived ovalbumin protein powder that replicates egg white functionality for large-scale food manufacturing without animal agriculture. The product serves food producers seeking sustainable, price-stable, and supply-resilient egg protein alternatives.

1 investor

One Health Studio is a venture studio that creates startups at the intersection of human health, animal health, and agriculture. It is powered by Alloy Partners.

1 investor

OneKind builds AI systems that capture and analyze animal behavior in clinical trials and production environments with traceable, reproducible, and auditable outputs for regulatory compliance. The company serves animal health researchers and pharmaceutical companies conducting regulated studies in companion and production animals.

1 investor

Onima is a biotechnology laboratory that upcycles food industry waste, starting with brewer's yeast from beer production, into complete, nutrient-rich foods. It offers brewers a large-scale solution to repurpose their yeast by-product back into the human food chain.

1 investor